Benzinga · Oct 27, 2026
Wedbush Reiterates Outperform on Immunome, Maintains $35 Price Target
Wedbush analyst David Nierengarten reiterates Immunome (NASDAQ:IMNM) with a Outperform and maintains $35 price target.
IM
NASDAQ · IMNM
Immunome, Inc.
Healthcare · Biotechnology
$18.21
Down-$0.08 (-0.44%)
Updated Nov 1, 2026, 9:29 AM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.79B
- P/E ratio
- -7.98
- Dividend yield
- 0.00%
- 52-week range
- $16.41 – $30.06
- Volume
- 1.27M
- Avg. volume
- 1.51M
Price performance · IMNM
IMNM price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
IMNM closed at $18.21 after 20 trading sessions, down 13.98% for the selected period.
- Last close
- $18.21
- Period change
- -13.98%
- Period low
- $16.47
- Period high
- $21.17
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $18.25 | $18.98 | $17.82 | $18.21 | 1.27M |
| Oct 29, 2026 | $18.88 | $19.30 | $18.11 | $18.29 | 877.93K |
| Oct 28, 2026 | $18.50 | $18.91 | $18.25 | $18.76 | 952.13K |
| Oct 27, 2026 | $17.95 | $19.00 | $17.50 | $18.77 | 1.23M |
| Oct 26, 2026 | $17.99 | $18.35 | $17.70 | $17.89 | 910.53K |
| Oct 23, 2026 | $18.13 | $18.25 | $17.65 | $17.99 | 1.38M |
| Oct 22, 2026 | $17.78 | $18.30 | $17.585 | $18.26 | 1.76M |
| Oct 21, 2026 | $17.99 | $18.44 | $17.85 | $18.00 | 1.55M |
| Oct 20, 2026 | $16.74 | $18.27 | $16.55 | $17.92 | 2.03M |
| Oct 19, 2026 | $16.60 | $16.92 | $16.44 | $16.77 | 1.14M |
| Oct 16, 2026 | $17.40 | $17.40 | $16.41 | $16.47 | 1.3M |
| Oct 15, 2026 | $17.31 | $17.61 | $17.08 | $17.40 | 1.62M |
| Oct 14, 2026 | $17.35 | $18.05 | $17.13 | $17.20 | 1.16M |
| Oct 13, 2026 | $19.06 | $19.155 | $17.43 | $17.58 | 2.21M |
| Oct 12, 2026 | $19.42 | $19.73 | $19.08 | $19.15 | 835.82K |
| Oct 9, 2026 | $19.05 | $19.72 | $18.88 | $19.55 | 998.19K |
| Oct 8, 2026 | $18.88 | $19.35 | $18.52 | $19.31 | 2.13M |
| Oct 7, 2026 | $18.94 | $19.555 | $18.9383 | $19.095 | 1.16M |
| Oct 6, 2026 | $21.35 | $21.43 | $18.92 | $19.31 | 2.31M |
| Oct 5, 2026 | $20.79 | $21.48 | $20.67 | $21.17 | 1.22M |
Latest IMNM news
The latest Smart Investors Daily articles mentioning IMNM.
Stock researchCompany · Overview
Company
Market Activity
Research & News
IMNM research
Overview
Company profile and research snapshot.
Company profile
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $28.25
- Implied upside
- —
- Analysts
- 18
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 27, 2026 | Wedbush | Outperform | — |
| Oct 16, 2026 | William Blair | Outperform | — |
| Oct 1, 2026 | Stifel | Hold | — |
| Sep 21, 2026 | Alliance Global Partners | Buy | — |
| Sep 10, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 26, 2026
Immunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026
BOTHELL, Wash., October 26, 2026--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the presentation of additional clinical data for varegacestat, its investigational, oral, once-daily gamma secretase inhibitor, at the 2026 European Society for Medical Oncology (ESMO) Congress. The data were featured in four presentations, including a rapid oral presentation on patient-repo
Benzinga · Oct 26, 2026
Immunome Showcases New Clinical Analyses Supporting Varegacestat's Profile In Desmoid Tumors At ESMO 2026
Rapid oral presentation highlights improvements in patient-reported symptom burden and physical function through week 48Four presentations build on the previously reported Phase 3 RINGSIDE resultsImmunome, Inc.
Benzinga · Oct 16, 2026
William Blair Initiates Coverage On Immunome with Outperform Rating
William Blair analyst Alethia Young initiates coverage on Immunome (NASDAQ:IMNM) with a Outperform rating.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
